Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Aerogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2024
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Aerogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 129Xe MRI
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Transplant
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
February 01, 2018
Lead Product(s) : 129Xe MRI
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 129Xe MRI
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
January 31, 2018
Lead Product(s) : 129Xe MRI
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable